Search Results - "MAMON, H. J"

Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older by Mak, R. H., Mamon, H. J., Ryan, D. P., Miyamoto, D. T., Ancukiewicz, M., Kobayashi, W. K., Willett, C. G., Choi, N. C., Blaszkowsky, L. S., Hong, T. S.

“…SUMMARY Randomized trials of chemoradiation for esophageal cancer have included very few patients age ≥ 75. In this retrospective study, we describe the…”
Get full text

Improvements in beam's eye view fiducial tracking using a novel multilayer imager by Harris, T C, Seco, J, Ferguson, D, Jacobson, M, Myronakis, M, Lozano, I Valencia, Lehmann, M, Huber, P, Fueglistaller, R, Morf, D, Mamon, H J, Mancias, J D, Martin, N E, Berbeco, R I

“…Electronic portal image devices (EPIDs) have been investigated previously for beams-eye view (BEV) applications such as tumor tracking but are limited by low…”
Get more information

The Survival Benefit From the Addition of Radiation to Chemotherapy in Gastric Cancer Patients Following Surgical Resection by Yang, T.S., Wang, X.F., Fairweather, M., Sun, Y.H., Mamon, H.J., Wang, J.P.

“…The survival benefit of radiation therapy in gastric cancer patients who underwent curative resection remains contentious. Gastric cancer patients who…”
Get full text

Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation by Mamon, H. J., Dahlberg, W., Azzam, E. I., Nagasawa, H., Muto, M. G., Little, J. B.

“…Purpose: The ataxia-telangiectasia mutated (ATM) gene encodes a protein kinase, the activation of which is an early event in the cellular response to ionizing…”
Get full text

A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer by Sanford, N. N., Catalano, P. J., Enzinger, P. C., King, B. L., Bueno, R., Martin, N. E., Hong, T. S., Wo, J. Y., Mamon, H. J.

“…SUMMARY Preoperative chemoradiotherapy (CRT) with carboplatin/paclitaxel has been shown to increase survival in patients with esophageal cancer, including…”
Get full text

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer by Blaszkowsky, L.S., Ryan, D.P., Szymonifka, J., Borger, D.R., Zhu, A.X., Clark, J.W., Kwak, E.L., Mamon, H.J., Allen, J.N., Vasudev, E., Shellito, P.C., Cusack, J.C., Berger, D.L., Hong, T.S.

“…To determine the maximal tolerated dose of erlotinib when added to 5-fluorouracil (5-FU) chemoradiation and bevacizumab and safety and efficacy of this…”
Get full text

Allergic Skin Reactions to Anticonvulsant Medications in Patients Receiving Cranial Radiation Therapy by Mamon, Harvey J., Wen, Patrick Y., Burns, Anne C., Loeffler, Jay S.

“…Purpose: Erythema multiforme and Stevens‐Johnson syndrome have been associated with anticonvulsant medications (AEDs) in patients with brain tumors receiving…”
Get full text

Oncogenes, growth factors, and signal transduction by Druker, B J, Mamon, H J, Roberts, T M

Get more information

Interleukin-2-triggered Raf-1 expression, phosphorylation, and associated kinase activity increase through G1 and S in CD3-stimulated primary human T cells by ZMUIDZINAS, A, MAMON, H. J, ROBERTS, T. M, SMITH, K. A

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 Induce Rapid Phosphorylation and Activation of the Proto-Oncogene Raf-1 in a Human Factor-Dependent Myeloid Cell Line by Kanakura, Yuzuru, Druker, Brian, Wood, Kenneth W., Mamon, Harvey J., Okuda, Keiko, Roberts, Thomas M., Griffin, James D.

“…The product of the c-raf-1 proto-oncogene, Raf-1, is a 74.000- dalton cytoplasmic serinehhreonine protein kinase that has been implicated as an intermediate in…”
Get full text

Quantification of Interfraction Gastric Motion by Daily Magnetic Resonance Imaging and Implications for Radiation Treatment Planning by Milligan, M.G., Huynh, E., Cagney, D.N., Mamon, H.J.

“…Accurate radiation therapy targeting for stomach cancer is challenging given daily variations in the stomach's size and position. We evaluated daily MR-based…”
Get full text

Adjuvant Treatment of Colorectal Cancer by Wolpin, Brian M, Meyerhardt, Jeffrey A, Mamon, Harvey J, Mayer, Robert J

“…Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer‐related death…”
Get full text

Beam's-Eye-View Imaging of Liver SBRT With a Novel Multi-Layer Imager by Harris, T., Seco, J., Ferguson, D., Jacobson, M., Myronakis, M., Lozano, I.Valencia, Lehmann, M., Huber, P., Fueglistaller, R., Morf, D., Mamon, H.J., Mancias, J.D., Martin, N.E., Berbeco, R.I.

“…Beams-eye view (BEV) imaging during radiation therapy can be used for real-time localization of the treatment target. However, clinical implementation is…”
Get full text

A Prospective Clinical Trial Evaluating Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART) for Pancreatic Cancer by Roberts, H.J., Shin, K.Y., Catalano, P.J., Huynh, E., Williams, C.L., Han, Z., Vastola, M., Ampofo, N., Leeman, J.E., Mamon, H.J., Mancias, J.D., Lam, M., Martin, N.E., Huynh, M.A., Mak, R.H., Singer, L., Cagney, D.N.

“…The use of ablative stereotactic body radiation therapy (SBRT) in pancreatic cancer is constrained by nearby radiation-sensitive organs. Magnetic resonance…”
Get full text

Impact of Stereotactic MR-Guided Adaptive Radiation Therapy on Early Clinical and Dosimetric Outcomes in Patients With Pancreatic Cancer by Roberts, H.J., Huynh, E., Williams, C.L., Han, Z., Vastola, M., Ampofo, N., Leeman, J.E., Mamon, H.J., Mancias, J.D., Lam, M., Martin, N.E., Huynh, M.A., Mak, R.H., Singer, L., Cagney, D.N.

“…Dose escalated stereotactic body radiotherapy (SBRT) may improve both local control and overall survival for patients with pancreatic cancer. However,…”
Get full text

PhaseI/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer by BLASZKOWSKY, L. S, RYAN, D. P, SHELLITO, P. C, CUSACK, J. C, BERGER, D. L, HONG, T. S, SZYMONIFKA, J, BORGER, D. R, ZHU, A. X, CLARK, J. W, KWAK, E. L, MAMON, H. J, ALLEN, J. N, VASUDEV, E

Get full text

A prospective study of capecitabine (cape), oxaliplatin (ox), bevacizumab (B), and radiation therapy (RT) (CAPOX-B RT) in patients with locally advanced or R1 biliary cancers: High risk of liver failure with extended hepatectomy by Hong, T. S., Ryan, D. P., Blaszkowsky, L. S., Mamon, H. J., Berger, D., Fernandez-del Castillo, C., Zhu, A. X.

“…Abstract only…”
Get full text

Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease by Schoenfeld, J. D., Mamon, H. J., Blaszkowsky, L. S., Enzinger, P. C., Wo, J. Y., Allen, J. N., Wadlow, R. C., Ryan, D. P., Hong, T. S.

“…Abstract only 110 Background: Anthracycline chemotherapy has been associated with radiation-induced liver disease (RILD). We sought to compare the incidence of…”
Get full text

Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 by Fuchs, C. S., Tepper, J. E., Niedzwiecki, D., Hollis, D., Mamon, H. J., Swanson, R., Haller, D. G., Dragovich, T., Alberts, S. R., Bjarnason, G. A., Willett, C. G., Enzinger, P. C., Goldberg, R. M., Venook, A. P., Mayer, R. J.

“…Abstract only…”
Get full text

A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC) by Blaszkowsky, L. S., Hong, T. S., Zhu, A. X., Kwak, E. L., Mamon, H. J., Shellito, P. C., Cusack, J. C., Berger, D., Horgan, K., Ryan, D. P.

“…Abstract only 4106 Background: The German Rectal Cancer Study Group established neoadjuvant therapy as a standard of care in patients with T3/T4 rectal cancer…”
Get full text